/

Sociétés

Ag

Non vérifié

Agendia, Inc.

Ce que nous écrivons

BiotechnologieIndustrieOncologieSantéScience

19 communiqués de presse

Voir tous les communiqués de presse

31/03/2026

Industrie

Santé

Oncologie

Genomic Profiling with MammaPrint® + BluePrint® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer

Source

Émetteur

1.00

0

12/08/2025

Science

VIH, SIDA et maladies auto-immunes

Biotechnologie

Santé Publique

Santé

Oncologie

Analyse de marché

Industrie

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

Source

Émetteur

1.00

0

27/05/2025

Événements

Science

Biotechnologie

Médecine - Divers

Santé

Santé Publique

Oncologie

Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO® Annual Meeting

Source

Émetteur

1.00

0

15/05/2025

Événements

Science

Équipement médical et sanitaire

Biotechnologie

Médecine - Divers

Santé

Oncologie

Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting

Source

Émetteur

1.00

0

06/05/2025

Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025

Source

Émetteur

1.00

0

24/04/2025

Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting

Source

Émetteur

1.00

0

11/02/2025

Ampliata l'indicazione di rimborso di MammaPrint® in Belgio

Source

Émetteur

1.00

0

11/02/2025

MammaPrint® Reimbursement Indication Extended in Belgium

Source

Émetteur

1.00

0

09/01/2025

Agendia, Inc. presenta un'analisi di un 2024 coronato dal successo

Source

Émetteur

1.00

0

09/01/2025

Agendia, Inc. Provides Review of Successful 2024

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0